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Purpose: The side effects of radiotherapy induced on healthy tissue limit its use. To
overcome this issue and fully exploit the potential of radiotherapy to treat cancers, the firstin-class radioenhancer NBTXR3 (functionalized hafnium oxide nanoparticles) has been
designed to amplify the effects of radiotherapy.
Patients and Methods: Thanks to its physical mode of action, NBTXR3 has the potential
to be used to treat any type of solid tumor. Here we demonstrate that NBTXR3 can be used
to treat a wide variety of solid cancers. For this, we evaluated different parameters on a large
panel of human cancer models, such as nanoparticle endocytosis, in vitro cell death induc
tion, dispersion, and retention of NBTXR3 in the tumor tissue and tumor growth control.
Results: Whatever the model considered, we show that NBTXR3 was internalized by cancer
cells and persisted within the tumors throughout radiotherapy treatment. NBTXR3 activated
by radiotherapy was also more effective in destroying cancer cells and in controlling tumor
growth than radiotherapy alone. Beyond the effects of NBTXR3 as single agent, we show
that the antitumor efficacy of cisplatin-based chemoradiotherapy treatment was improved
when combined with NBTXR3.
Conclusion: These data support that NBTXR3 could be universally used to treat solid
cancers when radiotherapy is indicated, opening promising new therapeutic perspectives of
treatment for the benefit of many patients.
Keywords: radiotherapy, radioenhancer, nanoparticle, NBTXR3, cancer
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Currently, approximately 50% of cancer patients will receive radiotherapy (RT) as part
of their treatment.1 Despite progress in development of radiotherapeutic oncology,
computer technology and medical imaging technology, the undesirable effects of RT on
healthy peripheral tissues still limits the dose usable in patients. The recent develop
ment of the first-in-class radioenhancer NBTXR3 (functionalized hafnium oxide
nanoparticles) opened new avenues to address this major therapeutic issue. NBTXR3
is administered by a single intratumoral injection before RT. Before RT, NBTXR3 is
inert (“off” status) but during RT treatment, the high electron density of NBTXR3
allows a high probability of interaction with incoming ionizing radiation, increasing
energy dose deposit within cells (“on” status). Thanks to its physical mode of action,
RT-activated NBTXR3 (NBTXR3+RT) is expected to be effective in all types of solid
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tumors. NBTXR3 can therefore lead to either better efficacy
with the same radiation dose2–4 or similar efficacy than RT
with a lower radiation dose. Antitumor efficacy of NBTXR3
+RT was demonstrated in a subset of tumors in preclinical
settings,2,4 and more recently demonstrated clinically mean
ingful benefit for patients with locally advanced Soft Tissue
Sarcoma compared to RT alone, in the randomized controlled
Phase II/III Act.in.Sarc study (NCT02379845).5 Other nano
particles using atoms with high electron density, such as gold
nanoparticles, eg, are currently under development in the
field of radiotherapy.6–9
In this article, we sought to demonstrate that NBTXR3
could be used to effectively treat any type of solid tumor,
using a large panel of human tumors originating from
different organs/tissues. We analyzed the capacity of
these nanoparticles to be internalized by cancer cells and
their retention within the tumors after intratumoral injec
tion. We also studied the ability of NBTXR3+RT to
improve cancer cell destruction and tumor growth control,
compared to RT alone. In all the cancer cell lines tested
here, NBTXR3+RT showed greater efficacy than RT alone.
We also demonstrated that NBTXR3 can improve the
efficiency of chemoradiation treatment with cisplatin
(CDDP).

Materials and Methods
Cell Culture and Reagents
The human cancer cell lines Detroit 562 (#CCL-138, phar
yngeal carcinoma), FaDu (#HTB-43, squamous cell phar
yngeal carcinoma), HT1080 (#CCL-121, fibrosarcoma),
MIA PaCa-2 (#CRL-1420, pancreas carcinoma), NCIH460 (#HTB-177, large cell lung carcinoma) and T98G
(#CRL-1690, glioblastoma) were purchased from ATCC.
The human cancer cell lines CAL-33 (#ACC 447, tongue
squamous cell carcinoma), DU-145 (#ACC 261, prostate
carcinoma), HEP-3B (#ACC 93, hepatocellular carci
noma), LNCaP (#ACC 256, prostate carcinoma) and PC3 (#ACC 465, prostate adenocarcinoma) were purchased
from DSMZ. The human cancer cell lines MDA-MB-231luc-D3-H2LN (breast adenocarcinoma) and NCI-H460Luc2 (large cell lung carcinoma) were purchased from
Caliper. Cells were cultivated according to manufacturer’s
recommendations and were controlled for mycoplasma by
an independent laboratory (Clean Cells). NBTXR3
(Nanobiotix) is a sterile aqueous suspension of functiona
lized crystal hafnium oxide (HfO2) spherical nanoparticles
with a size centered on 50nm, determined by dynamic
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light scattering technique (Zetasizer NanoZS, Malvern
Instruments Ltd, Worcestershire, UK), bearing a marked
negative surface charge (–50mV) in aqueous solution at
pH 6–8,2,4 estimated by zeta potential analysis (Zetasizer
NanoZS). Cisplatin (CDDP) was obtained from Sigma
Aldrich.

Mice and Patient Derived Xenograft
Models
Female immunodeficient NMRI-nu mice (6-weeks-old)
were used for in vivo experiments (Janvier Labs), except
for prostate cancer cell lines (PC-3, LNCaP, DU-145),
where males have been used. For experiments with
Patient Derived Xenograft LPS80T3 (obtained by direct
transplantation of a poorly differentiated human grade 3
retroperitoneal malignant fibrous histiocytoma) and PAC120 (obtained from a hormone-dependent prostate primary
adenocarcinoma) models, 8-weeks-old Hsd:Athymic nudeFOXn1 female and 5-weeks-old Hsd:Athymic nudeFOXn1 male were used, respectively (XenTech). Mice
were maintained under pathogen-free conditions in the
animal facility. All animal experiments were carried out
in compliance with French and European laws and regula
tions (European Directive 2010/63 EU). The local institu
tional animal ethics board and French Ministère de la
Recherche approved all mouse experiments.

Radiotherapy
For in vitro experiments, cells were irradiated at various
doses according to the study, delivered as a single dose,
using a 200kV X-ray source (NDI 226, Varian). For
in vivo experiments, subcutaneous tumors were irradiated
with various doses, using the same device as for in vitro
experiments, excepted for PC-3 tumors irradiated using
a 150kV X-ray source (CellRad, Faxitron), and NCIH460 tumors irradiated using a 310kV X-ray source
(Therapax, Agfa NDT). Selective irradiation of the tumor
on mice was performed by the interposition of a lead
shield, allowing full protection of the rest of the body,
including proximal lymph nodes.

Uptake Analysis by Transmission
Electronic Microscopy
Cells were seeded into 6-well plates (in duplicate) at the
density of 20,000 cells/cm2. Once cells were attached to
the plate, different doses of NBTXR3 were added over
night, according to the cell line considered (ranging from
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100µM to 800µM), as indicated on Figure 1. Cells were
then pre-fixed with 2.5% glutaraldehyde in cacodylate
0.1M at pH 7.4 (Sigma Aldrich) for 2 hours. Cells were
subsequently post-fixed with 1% osmium tetroxide (Sigma
Aldrich) for 45 minutes, washed and dehydrated in graded
concentrations of ethanol (50%, 70%, 95% and 100%)
(Sigma Aldrich). Cell samples were embedded with
EPON (Oxford Instruments). The resin sample block was
trimmed, 90µm thin sectioned to thickness of 70nm, (dia
tome diamond knives, Euromedex). Thin sections (70nm)
were collected onto 200 mesh cooper palladium grids, and
counterstained with lead citrate before examination with
a Zeiss EM 902 transmission electron microscope (TEM)
at 80KV (UR 1196 GPL: Génomique et Physiologie de la
Lactation - MIMA2 – plateau de Microscopie
Electronique – Jouy-en-Josas). Microphotographs were
acquired using MegaView III CCD camera and analyzed
with ITEM software (Eloïse). Ten (10) cells were observed
to estimate NBTXR3 nanoparticle cell uptake.

In vitro Cell Death Analysis
For clonogenic assays, cells were seeded in triplicate into
6 well plates in a range of 200–10,000 cells/well depend
ing on the test condition and radiation dose. Once cells
were attached to the plate, 50µM to 800µM NBTXR3 was
added. Different doses of X-rays were delivered 16 hours
post NBTXR3 treatment. The cells were cultured up to 15
±2 days at 37°C under 5% CO2. The colonies were fixed
and stained with crystal violet (Sigma) (25% in EtOH)
2 mL/well. All colonies of 50 cells or more were then
counted. For clonogenic assay with NCI-H460-Luc2 cells,
the same protocol was followed except that cells were
exposed to 725nM of CDDP for 6 hours or 405nM of
CDDP for 16 hours. Then, the medium was replaced by
fresh medium without CDDP before irradiation.

Tumor Growth Control Experiments
For the in vivo tumor growth control assays, cells were
subcutaneously injected into one flank of mice. Once the
tumor had grown (50–120 mm3), mice were randomized to
the different groups. A volume of NBTXR3 suspension (or
vehicle) corresponding to 25% of the baseline tumor
volume was injected into the tumor. After 24 hours,
tumors were irradiated. The non-tumor parts of the mice
were shielded by lead blocks. For chemoradiotherapy
experiments with NCI-H460 cells, CDDP (1mg.kg−1)
was administered by intraperitoneal injection two hours
prior to RT, daily over 5 consecutive days. Length (L)
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and width (W) of tumors were measured 2–3 times per
week using a digital caliper. Tumor volumes were calcu
lated using the formula (L×W2/2).

In vivo µCT Analysis
MicroComputerized Tomography (µCT) was used for visua
lization, evaluation of 3D dispersion and retention of
NBTXR3 within the tumor. For µCT acquisition, mice
were anesthetized using isoflurane (delivered as 1–3% for
maintenance; up to 5% for induction) in oxygen from
a precision vaporizer. Micro-CAT II CT scanner (Siemens)
in which X-rays were generated at 80 kVp and 500 mA was
used as imaging acquiring equipment (Voxcan).

Statistical Analysis
For the clonogenic assays, the studies have been indepen
dently repeated at least three times. Results are expressed
as mean of surviving fraction (SF) ± SD. The results were
analyzed by one-way ANOVA. For in vivo CDDP experi
mentation, tumor growth curve was analyzed using mixed
linear modeling (MLM), performed with R statistics soft
ware. GraphPad Prism 7.04 software was used to perform
statistical analyzes. Significance was defined at the level of
p<0.05.

Results
NBTXR3 is Endocytosed by Cancer Cells
The ability of tumor cell lines to internalize NBTXR3
nanoparticles was assessed by TEM in eight cell lines
originating from head and neck, lung, breast and prostate
cancer (Figure 1, Table 1). In all these cell lines, nanopar
ticles were systematically detected in the cytoplasm, where
they formed clusters of various sizes distributed through
out the cell. The amount of intracellular NBTXR3 greatly
varied across the cell lines analyzed. Among the prostate
cancer cell lines analyzed, PC-3 internalize the most, and
LNCaP internalize the least of NBTXR3 nanoparticles
(Figure S1). However, no nanoparticles were observed in
the nuclei, regardless of the cell line considered.

RT-Activated NBTXR3 Kills Cancer Cells
More Efficiently Than RT Alone
We sought to determine the impact of NBTXR3+RT on cell
death induction, compared to RT alone. For this, we carried
out clonogenicity tests on five cell lines originating from
glioblastoma, prostate, liver, and pancreas cancers, varying
the concentration of NBTXR3 (50–800µM) and the dose of
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Figure 1 NBTXR3 nanoparticles are endocytosed by cancer cells and form clusters in the cytoplasm. Transmission electronic microscopy (TEM) representative images of
NBTXR3 nanoparticles uptake, forming clusters in CAL-33, FaDu, NCI-H460-Luc2, MDA-MB-231-luc-D3-H2LN (upper panel) and DU-145, LNCaP, PC-3, Detroit 562 cells
(lower panel). Cells were treated overnight with NBTXR3. 100µM, 400µM and 800µM indicate concentrations of NBTXR3 added to cells; arrows indicate NBTXR3
clusters.
Abbreviations: Cyt, cytoplasm; CTL, control cells (no NBTXR3); Nuc, nucleus.

RT (1–6Gy) used (Figure 2, Table 1). No significant clono
genic toxicity of NBTXR3 without RT was observed at the
tested concentrations. For all cell lines studied, a NBTXR3
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dose-dependent increase in cell death was observed from
2Gy, compared to RT alone. For some concentrations of
NBTXR3, this difference becomes significant, compared to
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Table 1 Compilation of Preclinical Studies Performed with NBTXR3
Tissue Origin

Brain

Cancer Type

Glioblastoma

Cell Line Name

42MG-BA

In vitro

In vivo

TEM

Efficacy

µCT

Efficacy

[2, 4]

[4]

[20]

[20]

[20]

[2, 4]

[2, 4]

●

T98G
Breast

Adenocarcinoma

MDA-MB-231-luc-D3-H2LN

Colon

Carcinoma

CT26

●

HCT116

[2, 4]

[4, 19]

Adenocarcinoma

HT29

[4]

[4]

Tongue squamous cell carcinoma

CAL-33

●

[4]

●

●

Pharyngeal squamous cell carcinoma

Detroit 562

●

Hypopharyngeal squamous cell carcinoma

FaDu

●

●, [4]

●

●

Liver

Hepatocellular carcinoma

HEP-3B

Lung

Large cell lung carcinoma

NCI-H460-Luc2

●

●, [4]

●

●

Lung metastasis

Fibrosarcoma

Hs913T

[4]

[4]

Pancreas

Carcinoma

MIA PaCa-2

Ductal adenocarcinoma

PANC-1

[4]

[4]

Carcinoma

DU-145

●

●

●

●

Adenocarcinoma

LNCaP

●

Head and Neck

Prostate

●

●

●

PAC-120
●

PC-3
Soft tissue

Rhabdomyosarcoma

A673

Fibrosarcoma

HT1080

Liposarcoma

LPS80T3

●

●

●
[2, 4]

[2, 4]

●

[2, 4]
●

●

Notes: ● Studies presented in this article; blank boxes indicate that the study has not been done. References of previously published data are indicated in square brackets.

RT alone and an increase in the Dose Enhancement Factor
(DEF) can be observed (Figure 2B).

Distribution and Retention of NBTXR3 in
Tumor
The intended route of administration for NBTXR3 is a single
intratumoral injection.5,10 For treatment with NBTXR3 to be
effective, it is essential that the nanoparticles remain within the
tumor throughout the RT sessions, whatever the type of solid
tumor injected. Thus, we evaluated the dispersion and reten
tion of NBTXR3 in various type of tumor at one day and
several days after injection. To do this, we injected NBTXR3
into subcutaneous tumors of six different mice models (cell

International Journal of Nanomedicine 2021:16

lines and PDX), originating from lung, prostate, sarcoma, and
head and neck cancers (Figure 3, Table 1). The high density of
the nanoparticles renders them radio-opaque and easy to visua
lize by µCT (Figure 3A). NBTXR3 localization was thus
assessed the day after intratumoral injection (D02) and then
at different post-injection time points (Figure 3B). These
studies showed that, in all tumors, nanoparticles were found
well distributed inside the tumor mass the day after intratu
moral injection. The µCT performed one or two weeks after
the injection showed that the nanoparticles were still localized
in the tumor. Remarkably, in the PAC-120 PDX model, which
has very slow tumor growth, the nanoparticles were still pre
sent 50 days after the first µCT.
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A

B

Figure 2 NBTXR3 activated by RT kills more cancer cells than RT alone. (A) Clonogenic assay in DU-145, PC-3, HEP-3B (upper panel), T98G, and MIA PaCa-2 (lower panel). Cells
were treated overnight with various concentrations of NBTXR3, then irradiated. After several days, colonies were stained using crystal violet and counted. Presented data were
obtained from at least three independent experiments (n≥3). Data are represented as surviving fraction percentage (SF (%)) ± SEM. (B) Surviving fraction (SF) and corresponding
Dose Enhancement Factor (DEF) for each condition. Percentage of surviving fraction (SF) ± SD and dose enhancement factor (DEF) ± SD. n ≥ 3. *p<0.05; **p<0.01; ***p<0.001.
Abbreviation: N.D., not determined.

2766

submit your manuscript | www.dovepress.com

DovePress

International Journal of Nanomedicine 2021:16

Dovepress

Zhang et al

A

B

Figure 3 After intratumoral injection, NBTXR3 distributes and remains in the tumor. (A) Thanks to its composition, NBTXR3 is easily observable in the tumor by µCT
(white areas indicated by the arrows). (B) 3D representation of the of NBTXR3 nanoparticles distribution within tumor tissues of models NCI-H460-Luc2, PC-3 and
LPS80T3 (upper panel), DU-145, FaDu (middle panel), CAL-33 and PAC-120 (lower panel), after µCT analysis. Indicated day corresponds to time post-intratumoral injection
(D01).
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Figure 4 NBTXR3 activated by radiotherapy controls tumor growth more effectively than radiotherapy alone. (A) The ability of NBTXR3 to control tumor growth better
than radiotherapy as well as the impact on survival was tested in nude mice bearing a tumor of CAL-33, FaDu, LPS80T3, HT1080 (left column), DU-145, PC-3 and NCIH460-Luc2 (right column). Number of mice per group: 5–6. Tumor growth curves are expressed as mean relative tumor volume (RTV) ± SEM. (B) Table indicative of the
types of cancers tested, the doses of RT used and the source of radiotherapy. (C) Tumor doubling time, optimal T/C and median survival of the in vivo experiment results.

RT-Activated NBTXR3 Improves Tumor
Growth Control
To confirm the ability of NBTXR3 to destroy tumor cells
more efficiently than RT alone in vivo, we used seven
human cell lines, derived from six distinct tumor types
(tongue, prostate, pharynx, fibrosarcoma, liposarcoma and
lung), subcutaneously injected in nude mice (Figure 4,
Table 1). In the absence of RT, the injection of NBTXR3
did not affect tumor growth, thus confirming the inert
nature of these nanoparticles in their “off” status observed
in vitro (Figure 4A and C). In contrast, treatment with
NBTXR3+RT better controlled tumor growth and
improved survival regardless of the model considered,
compared to radiotherapy alone (Figure 4). NBTXR3+RT
thus markedly increased the doubling time of tumor
growth, the median survival, and reduced the optimal T/
C (Figure 4C). Only the FaDu and PC-3 models did not
show an improvement in their median survival, but an
increase in overall survival could still be observed
(Figure 4A and C). In the well-known radioresistant DU145 tumor model,11–13 RT (2x4Gy) had no significant
effect on tumor growth. In stark contrast, the treatment
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of DU-145 tumors by RT-activated NBTXR3 resulted in
a strong tumor growth delay. The tumor doubling time
increased from 9 to 20 days, for RT and NBTXR3+RT,
respectively (Figure 4A and C).

NBTXR3 Improves the Efficacy of
Chemoradiotherapy with Cisplatin
We sought to determine the ability of NBTXR3 to improve
the effectiveness of chemoradiation with cisplatin (CDDP
+RT). We first performed clonogenicity tests using the
NCI-H460-Luc2 cell line. Cells were treated with the
CDDP 6h or 16h before RT, in the presence or not of
NBTXR3, to highlight a possible time effect. The results
show that NBTXR3+RT was as effective as CDDP+RT at
destroying cancer cells (Figure 5A and B). Interestingly,
the addition of NBTXR3 to CDDP+RT treatment signifi
cantly improved cell destruction, whatever the time con
sidered. We then compared the effects of RT, CDDP+RT,
NBTXR3+RT and NBTXR3+CDDP+RT treatments on
tumor growth control, in mice bearing an NCI-H460
tumor (Figure 5C). The tumor growth delay was extended
for mice receiving NBTXR3 activated by radiotherapy or

International Journal of Nanomedicine 2021:16
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B

C

Figure 5 RT-activated NBTXR3 improves the efficacy of cisplatin. The capacity of NBTXR3 to kill cancer cells, in combination or not with cisplatin (725nM of CDDP for 6
hours or 405nM of CDDP for 16 hours), was analyzed by clonogenic assay on the NCI-H460-Luc2 cell line, after an incubation of 6h (A) or 16h (B) with cisplatin before
irradiation. Presented data were obtained from five independent experiments (n=5). Data are represented as surviving fraction percentage (SF (%)) ± SEM. Surviving fraction
(SF) and corresponding Dose Enhancement Factor (DEF) for each condition are indicated and time point are indicated on the lower panel. *p<0.05 vs CTL. (C) The ability of
NBTXR3 to control tumor growth was compared in combination or not with cisplatin (CDDP, 1mg.kg−1). Tumor growth curves are expressed as mean tumor volume (TV)
± SEM. Number of mice per group: 5.
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cisplatin and radiation, compared with mice receiving
radiation alone (~17 days versus ~22 days,). Histology
analyses revealed that NBTXR3+RT reduced cell prolif
eration and induced apoptosis, similarly to CDDP+RT
(Supplementary Materials and Methods and Figure S2).
NBTXR3 +CDDP+RT treatment markedly prolonged
tumor growth compared with RT alone (~17 days versus
~25 days delay).

Discussion
The first-in-class nanosized radioenhancer NBTXR3 has
been developed to multiply the effects of RT without
generating additional side effects.5,10,14 Its effectiveness
has been recently successfully demonstrated in a Phase
II/III clinical study in locally advanced soft tissue
sarcomas.5 In the preclinical studies presented in this arti
cle, we wanted to demonstrate that NBTXR3 can be used
to treat any type of solid cancer, and that its combination
with chemoradiotherapy treatments can improve their
effectiveness.
A cellular uptake of NBTXR3 was evidenced by TEM
in all height cancer cell lines studied originating from
different organs (pharynx, tongue, lung, breast, and pros
tate). The number of nanoparticles detected in the cyto
plasm varies depending on the cell line used, similar to
previously published data.4 These differences cannot be
explained by the organ origin of the cells, since such
a difference can be observed between the PC-3 and
LNCaP cell lines, both originating from prostate cancer
(Figure S1). We hypothesize that this could be due to
various internalization capacities between cell lines, eg,
the clathrin-mediated endocytosis pathway, known to be
an important entry point for internalization of
nanoparticles,15 but additional analyses must be performed
to confirm this. Another shared characteristic observed in
TEM analysis was the capacity of all cell lines to form
nanoparticle clusters in their cytoplasm. This concentra
tion of the nanoparticles suggests a common intracellular
trafficking mechanism. Autophagy may possibly explain
nanoparticle aggregates because this process is frequently
activated by nanoparticles.16 However, this may not be the
only process involved since nanoparticle aggregates were
also observed in the autophagy-deficient DU-145 cell line
(Figure 1).17 Additional experiments are required to iden
tify the endocytosis and intracellular trafficking pathways
involved. In addition, nanoparticles have never been
observed in the nucleus of cells, which could be explained
by their size (centered on 50 nm). Indeed, it has previously
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been reported by Wu et al18 that only <50nm silver nano
particles can enter the nucleus. Considering previously
published results,2,4 the analyzes carried out in fourteen
cell lines from ten different organs/tissues clearly show
that the endocytosis of NBTXR3 nanoparticles, as well as
their clustering and exclusion from the nucleus are char
acteristics universally shared between cancer cell lines
(Table 1).
All the clonogenic assays presented in this article show
that NBTXR3+RT increased cancer cell death, in a dosedependent manner, compared to the same dose of RT
alone. Considering previous studies,2,4,19,20 the enhance
ment of cell death following NBTXR3+RT treatment com
pared to RT alone has now been demonstrated in fifteen
different cancer cell lines originating from nine different
organs/tissues (Figure 6, Table 1). This also clearly
demonstrates that, thanks to its radioenhancing capacity,
NBTXR3 can kill any type of cancer cell. It is assumed
that this is also the case for any other solid tumor cancer
cells. This superior capacity of NBTXR3 activated by RT
to destroy cancer cells, compared to RT alone, could make
it possible to reduce the dose per fraction, while maintain
ing the same efficacy. This could have direct applications
for patients, helping to limit the side effects of RT, thereby
improving the patient’s quality of life and costs to the
healthcare system. The improvement in cell death goes
beyond a simple decrease in the number of cancer cells.
Indeed, the heightened release of tumor-associated anti
gens triggered by NBTXR3+RT treatment could play
a critical role in the priming or amplification of the adap
tive antitumor immune response, as recently reported in
the CT26 mouse colorectal model.20
Preclinical and clinical studies have not revealed any
leakage of NBTXR3 into surrounding tissues and showed
that NBTXR3 remains within the tumor throughout RT
treatment.2,10,20 To expand these results, we examined the
retention of NBTXR3 in seven different tumor models by
µCT. We demonstrate that NBTXR3 was detectable within
the tumor from few days to several weeks after intratu
moral injection. Considering previously published precli
nical data, the retention of NBTXR3 nanoparticles in
tumor has been demonstrated in nine different cancer cell
lines originating from six different organs/tissues (Figure
6, Table 1). We postulate that the “long-term” retention of
NBTXR3 observed in these tumors could be due, at least
in part, to the internalization of the nanoparticles by cells,
as demonstrated in the different TEM analysis, but addi
tional studies are needed to confirm this hypothesis.
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Figure 6 Review of studies with NBTXR3. The various experiments carried out in vitro and in vivo on the various human models demonstrated the effectiveness of
NBTXR3 and its capacity to treat any kind of solid tumor. These preclinical results have been confirmed in a Phase II/III clinical trial in patients with soft tissue sarcoma, and
other Phase I trials are currently in progress.

Nonetheless, we can conclude that the distribution and
retention of NBTXR3 in solid tumors are universal
phenomena.
NBTXR3 nanoparticles have been designed to act as
radioenhancers, only producing an antitumor effect when
they receive ionizing radiation (“on” status). Without RT
(“off” status), the nanoparticles are then “inert”. The dif
ference between “off” and “on” status were previously
reported2,4,19 and confirmed here by in vitro clonogenicity
studies. These properties have also been demonstrated in 
vivo2,20 and confirmed by the new studies presented here.
The “off” status of NBTXR3 had no effect on tumor
growth, compared to the control, whatever the model
considered. In contrary, the tumor growth control was
systematically improved in the presence of NBTXR3+RT
(“on” status), compared to RT alone, even in
a radioresistant tumor model. These results are in good
agreement with the previously published results2,5,20 and
support the possibility that, thanks to its physical mode of

International Journal of Nanomedicine 2021:16

action, the antitumor efficacy of NBTXR3 could be effi
cient in any type of solid tumor.
Carcinoma of the lung is the leading cause of cancerrelated death in both men and women,21 non-small cell
lung cancer (NSCLC) accounting for almost 75% of
cases.22 Concurrent chemoradiotherapy using cisplatin
(CDDP) regimen is currently the standard treatment for
stage III inoperable NSCLC.23,24 For elderly patients
inoperable and too frail to support treatment with cispla
tin, RT is the only therapeutic alternative, whose benefi
cial effects are limited. Based on its very good safety
profile reported in patients,10 NBTXR3 could open new
avenues for the treatment of these particularly frail
patients. In fact, the clonogenicity assays with CDDP or
NBTXR3, in combination with RT, show that NBTXR3
+RT is as efficient as CDDP+RT treatment to kill cancer
cells. On the other hand, similar efficacies were obtained
for both treatments in vivo. These promising results are
now tested in a Phase I clinical trial to treat patients too
frail to receive chemoradiotherapy with CDDP, and
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eligible only for RT (NCT02901483). Remarkably,
in vitro and in vivo results of CDDP+NBTXR3+RT
show that this combination improved the efficacy of
CDDP+RT. This suggests that patients usually treated
with this chemoradiotherapy could benefit from the addi
tion of NBTXR3 in their treatment. These results also
open up interesting new perspectives concerning the com
bination of NBTXR3 with other chemoradiotherapies,
such as, g, poly(ADP-ribose)polymerase inhibitors
(PARPi)25 or tyrosine kinase inhibitors (TKI).26
NBTXR3 activated by RT may also be valuable in com
binations with other therapies, such as immune checkpoint
inhibitors like anti-PD-1. Indeed, we recently showed in
immunocompetent mice that NBTXR3 activated by RT
was able to induce an antitumor immune response, produ
cing an abscopal effect.20
Taken together, the data presented so far support the
possibility that NBTXR3 could be universally used with
RT to treat any type of solid cancer.2,4,5,10,19,20 NBTXR3
opens promising new therapeutic perspectives of treatment
for the benefit of millions of patients. Several clinical trials
in HNSCC, liver cancers, as a single agent, or in combina
tion with chemotherapy in HNSCC and rectal cancer as well
as in combination with anti-PD-1 in HNSCC, lung or liver
metastasis from any primary cancer are currently in progress
to confirm the important therapeutic potential of NBTXR3.

Abbreviations
CDDP, cisplatin; DEF, dose enhancement factor; HNSCC,
head and neck squamous-cell carcinoma; PARPi, poly
(ADP-ribose) polymerase inhibitor; RT, radiotherapy; SF,
surviving fraction; TEM, transmission electron micro
scopy; TKI, tyrosine kinase inhibitor; µCT, X-ray microcomputed tomography.
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